Results 41 to 50 of about 4,182 (143)

NGEU and Vaccines Strategy in the Wake of the COVID‐19 Pandemic: Outgrowing the Regulatory State

, 2022
JCMS: Journal of Common Market Studies, Volume 60, Issue S1, Page 101-113, September 2022.
Manuele Citi, Caroline de la Porte
wiley   +1 more source

Data Resource Profile: COVid VAXines Effects on the Aged (COVVAXAGE)

International Journal of Population Data Science, 2023
Background To improve the assessment of COVID-19 vaccine use, safety, and effectiveness in older adults and persons with complex multimorbidity, the COVid VAXines Effects on the Aged (COVVAXAGE) database was established by linking CVS Health and ...
Kaleen Hayes, Daniel Harris, Andrew Zullo, Djeneba Audrey Djibo, Renae L. Smith-Ray, Michael S. Taitel, Tanya G. Singh, Cheryl McMahill-Walraven, Preeti Chachlani, Katherine Wen, Ellen P. McCarthy, Stefan Gravenstein, Sean McCurdy, Kristina E. Baird, Daniel Moran, Derek Fenson, Yalin Deng, Vincent Mor   +17 more
doaj   +1 more source

Effect of Heterologous Vaccination Strategy on Humoral Response against COVID-19 with CoronaVac plus BNT162b2: A Prospective Cohort Study

Vaccines, 2022
This study aimed to evaluate the mixed and homogeneous application of the inactivated SARS-CoV-2 vaccine CoronaVac (CV) and the mRNA vaccine BNT162b2 (BNT).
Hakan Demirhindi, Burak Mete, Ferdi Tanir, Ertan Kara, Filiz Kibar, Salih Cetiner, Aslihan Candevir, Sukriye Ece Akti   +7 more
doaj   +1 more source

Evidence–time dilemma in a pandemic with high mortality: Can outcome‐driven decision making on vaccines prevent deaths?

, 2022
Clinical and Translational Science, Volume 15, Issue 1, Page 5-8, January 2022.
Klaus Eckhardt
wiley   +1 more source

Humoral and T-cell response 12 months after the first BNT162b2 vaccination in solid organ transplant recipients and controls: Kinetics, associated factors, and role of SARS-CoV-2 infection

Frontiers in Immunology, 2023
IntroductionWe investigated humoral and T-cell responses within 12 months after first BNT162b2 vaccine in solid organ transplant (SOT) recipients and controls who had received at least three vaccine doses.
Omid Rezahosseini, Sebastian Rask Hamm, Line Dam Heftdal, Laura Pérez-Alós, Dina Leth Møller, Michael Perch, Michael Perch, Johannes Roth Madsen, Annemette Hald, Cecilie Bo Hansen, Jose Juan Almagro Armenteros, Mia Marie Pries-Heje, Rasmus Bo Hasselbalch, Rasmus Bo Hasselbalch, Kamille Fogh, Kamille Fogh, Ruth Frikke-Schmidt, Ruth Frikke-Schmidt, Linda Maria Hilsted, Erik Sørensen, Sisse Rye Ostrowski, Sisse Rye Ostrowski, Zitta Barrella Harboe, Zitta Barrella Harboe, Zitta Barrella Harboe, Kasper Iversen, Kasper Iversen, Kasper Iversen, Henning Bundgaard, Henning Bundgaard, Søren Schwartz Sørensen, Søren Schwartz Sørensen, Allan Rasmussen, Peter Garred, Peter Garred, Susanne Dam Nielsen, Susanne Dam Nielsen   +36 more
doaj   +1 more source

Assessment of humoral immune response to different COVID-19 vaccines in patients undergoing maintenance hemodialysis

Brazilian Journal of Nephrology, 2023
Introduction: The immune response to different Coronavirus Disease 2019 (COVID-19) vaccines is under-investigated in end-stage kidney disease (ESKD) patients, especially in the Middle East and North Africa.
Ayman Abd El-Hameed, Mohammed Fouad Ahmed, Ali Omar Ahmed Ehmemeed, Ahmad Mokhtar, Walid Ahmed Ragab Abdelhamid   +4 more
doaj   +2 more sources

Proteome Organization of COVID-19: Illustrating Targets for Vaccine Development

Journal of Pure and Applied Microbiology, 2020
‘COVID-19’ the recent virulent viral infection had influenced the lives of millions globally leading to both loss of life, economic and financial crisis. Coronavirus belongs to family coronaviridae with four genus viz.
Alok Bharadwaj, Nitin Wahi, Aditya Saxena, Divya Chaudhary   +3 more
doaj   +1 more source

Quantitative Analysis of Anti-N and Anti-S Antibody Titers of SARS-CoV-2 Infection after the Third Dose of COVID-19 Vaccination

Vaccines, 2022
We quantitatively analyzed SARS-CoV-2 antibody levels in patients after two doses of the ChAdOx1 nCoV-19 vaccine and the third BNT162b2 booster. We obtained 255 serum samples from 149 healthcare workers 1 and 4 months after the third dose.
Nuri Lee, Seri Jeong, Su Kyung Lee, Eun-Jung Cho, Jungwon Hyun, Min-Jeong Park, Wonkeun Song, Hyun Soo Kim   +7 more
doaj   +1 more source

Facing the challenge of viral mutations in the age of pandemic: Developing highly potent, broad‐spectrum, and safe COVID‐19 vaccines and therapeutics

, 2021
Clinical and Translational Medicine, Volume 11, Issue 1, January 2021.
Shan Su, Qian Wang, Shibo Jiang
wiley   +1 more source

Side Effects of mRNA-Based COVID-19 Vaccines among Young Adults (18–30 Years Old): An Independent Post-Marketing Study

Pharmaceuticals, 2021
Young adults had been widely perceived as a low-risk group for COVID-19 severity; therefore, they were deprioritised within the mass vaccination strategies as their prognosis of COVID-19 infection is relatively more favourable than older age groups.
Abanoub Riad, Andrea Pokorná, Jitka Klugarová, Natália Antalová, Lucia Kantorová, Michal Koščík, Miloslav Klugar   +6 more
doaj   +1 more source